We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo WHX Labs Dubai 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomarkers of Oral Cancer Discovered

By LabMedica International staff writers
Posted on 30 Apr 2019
Image: A histopathology of oral cancer: tumor islands can be seen infiltrating the connective tissues deep to the overlying oral epithelium. This carcinoma is moderately differentiated with a non-cohesive invasive pattern (Photo courtesy of University of Sheffield).
Image: A histopathology of oral cancer: tumor islands can be seen infiltrating the connective tissues deep to the overlying oral epithelium. This carcinoma is moderately differentiated with a non-cohesive invasive pattern (Photo courtesy of University of Sheffield).
Epigenetics, the non-genetic influences on gene expression, is a powerful mechanism capable of altering gene expression in cancer cells without changes to the DNA sequence, and can cause tumor progression.

Oral cancer is known for its high mortality rate in developing countries, but an international team of scientists hope its latest discovery will change that. The team has discovered epigenetic markers that are distinctly different in oral cancer tissues compared to the adjacent healthy tissues in patients.

Collaborating scientists from the University of Otago (Otago, New Zealand) and the Indian Statistical Institute (ISI, Kolkata, India) recruited 16 oral cancer patients in India, who were either tobacco smokers or chewers or of mixed habits, and took samples of both tumor and normal, adjacent tissue from them.

The team isolating the DNA in the samples, and discovered regions with altered epigenetic profiles in tumors cells compared to normal cells. They looked at one epigenetic mechanism, DNA methylation, which refers to the addition of methyl groups to DNA, like bookmarks. A total of 4,310 unique differentially methylated regions, mapping to 144 miRNA loci, were identified. Three distinct groups of miRNAs were differentially methylated in cancer tissues from smokers, chewers and mixed habitués. Hypermethylation of miR-503, miR-200a/b, miR-320b and miR-489 was associated with worse 5-year survival.

How these bookmarks are arranged could dictate the expression of genes and the spread of abnormal cells. Late diagnosis and poor prognosis are key problems associated with the high mortality rate of this cancer in developing countries. Of the 300,000 cases of tobacco associated oral cancer detected globally, 86% are from India. Aniruddha Chatterjee, PhD, a senior research fellow and co-author of the study, said, “This phenomenon is relatively new and under studied, particularly in oral cancer. This study is one of the first to identify epigenetic markers in oral cancer, using cutting-edge approaches.”

Roshni Roy, PhD, the lead author of the study, added, “We were also surprised to see that small molecules, called microRNA, were methylated or demethylated in the tumors from smokers or chewers or mixed habitués, suggesting that therapeutic intervention might be different in patients depending on the way the tobacco was abused.” The study was published on March 15, 2019, in the journal Epigenomics.

Related Links:
University of Otago
Indian Statistical Institute

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more